Piramal Consumer Healthcare is cutting new product launches by half and focusing on premiumizing its existing portfolio to target $200 million in revenue by 2030, CEO Sai Ramana Ponugoti said. The company is also expanding into adjacent product categories and doubling down on quick commerce to strengthen its market position, according to livemint.com.
The strategy involves narrowing the company’s focus to fewer but larger bets amid increasing competition in the over-the-counter drug market in India. Ponugoti explained that this approach allows Piramal Consumer Healthcare to allocate resources more efficiently and drive growth through premium products and new adjacent categories. The company is also leveraging quick commerce platforms to enhance distribution and consumer reach.
This shift reflects broader trends in the fast-moving consumer goods (FMCG) sector, where companies are prioritizing depth over breadth to improve profitability and brand strength. Piramal’s move to reduce product launches contrasts with earlier strategies focused on volume and variety, aligning with modern FMCG playbooks emphasizing premiumization and targeted expansion. The company’s $200 million revenue target by 2030 positions it as a significant player in India’s OTC healthcare market.
Piramal Consumer Healthcare’s CEO Sai Ramana Ponugoti shared these strategic updates in an interview published on June 28, 2026, by livemint.com, highlighting the company’s commitment to focused growth and innovation in the healthcare segment.